CSPC Pharmaceutical Group Ltd (CSPCY)
3.17
-0.05
(-1.55%)
USD |
OTCM |
Jun 21, 16:00
CSPC Pharmaceutical Group Enterprise Value: 7.900B for June 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 21, 2024 | 7.900B |
| June 20, 2024 | 8.049B |
| June 18, 2024 | 8.436B |
| June 17, 2024 | 8.510B |
| June 14, 2024 | 8.629B |
| June 13, 2024 | 8.748B |
| June 12, 2024 | 8.691B |
| June 11, 2024 | 8.778B |
| June 10, 2024 | 8.822B |
| June 07, 2024 | 8.822B |
| June 06, 2024 | 8.882B |
| June 05, 2024 | 8.786B |
| June 04, 2024 | 8.852B |
| June 03, 2024 | 8.376B |
| May 31, 2024 | 8.673B |
| May 30, 2024 | 8.822B |
| May 29, 2024 | 8.555B |
| May 28, 2024 | 8.983B |
| May 24, 2024 | 8.108B |
| May 23, 2024 | 7.989B |
| May 22, 2024 | 8.138B |
| May 21, 2024 | 8.376B |
| May 20, 2024 | 8.552B |
| May 17, 2024 | 8.525B |
| May 16, 2024 | 8.673B |
| Date | Value |
|---|---|
| May 15, 2024 | 8.615B |
| May 14, 2024 | 8.569B |
| May 13, 2024 | 8.822B |
| May 10, 2024 | 8.792B |
| May 09, 2024 | 8.659B |
| May 08, 2024 | 8.525B |
| May 07, 2024 | 8.436B |
| May 06, 2024 | 8.644B |
| May 03, 2024 | 8.703B |
| May 02, 2024 | 8.688B |
| May 01, 2024 | 8.227B |
| April 30, 2024 | 8.108B |
| April 29, 2024 | 8.375B |
| April 26, 2024 | 8.349B |
| April 25, 2024 | 8.138B |
| April 24, 2024 | 7.662B |
| April 23, 2024 | 7.424B |
| April 22, 2024 | 7.395B |
| April 19, 2024 | 7.071B |
| April 18, 2024 | 7.164B |
| April 17, 2024 | 7.080B |
| April 16, 2024 | 7.113B |
| April 15, 2024 | 7.206B |
| April 12, 2024 | 7.221B |
| April 11, 2024 | 7.519B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.105B
Minimum
Jul 22 2019
17.88B
Maximum
Jun 11 2021
11.08B
Average
10.99B
Median
Enterprise Value Benchmarks
| Sinovac Biotech Ltd | -7.011B |
| CASI Pharmaceuticals Inc | 48.51M |
| Zai Lab Ltd | 1.231B |
| Adagene Inc | 48.01M |
| LakeShore Biopharma Co Ltd | 94.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 191.54M |
| Revenue (Quarterly) | 1.054B |
| Total Expenses (Quarterly) | 805.15M |
| EPS Diluted (Quarterly) | 0.0646 |
| Gross Profit Margin (Quarterly) | 70.99% |
| Profit Margin (Quarterly) | 18.18% |
| Earnings Yield | 8.83% |
| Operating Earnings Yield | 10.54% |
| Normalized Earnings Yield | 8.828 |